Teladoc Health saw a serious boom during the COVID-19 pandemic, but with stagnant and declining revenue and a lack of profitability, this company looks like it might end up as a relic of a brief but bygone era.Though it's mercifully beginning to feel like a distant memory now, the aftereffects of the COVID-19 pandemic are still very much with us, though some have faded away faster than others. And Teladoc Health's (TDOC 3.81%) share price is proof of that.There were a handful of companies back in 2020 that ...

Core Insights - The global medical devices market is projected to grow from US$ 517.86 billion in 2024 to US$ 905.56 billion by 2033, with a CAGR of 6.4% from 2025 to 2033 [1][2] Market Growth Drivers - The market is experiencing dynamic growth due to increased focus on personalized care and early diagnostics, with significant investments in wearable sensors, robotic surgery systems, and advanced imaging tools [2] - The proliferation of digitally connected devices is evident, with an estimated 504 million wearable health monitors expected to ship worldwide in 2023 [2][4] - The US FDA granted clearances to over 2,900 novel medical technologies in the past year, indicating a strong innovation pipeline [2][4] Regional Insights - The United States, Germany, and China dominate global production, with the US having over 6,500 licensed device manufacturers in 2023 [3] - Germany exported advanced surgical instruments worth nearly US$ 28 billion last year, while China's output of single-use medical devices reached 65 billion units [3] - Asia Pacific is expected to register the highest growth rate of 7.1%, driven by strong manufacturing bases and supportive government policies [9][10] Product Innovations - Wearable healthcare solutions are redefining chronic condition management, with 504 million wearable shipments in 2023, including devices for heart rate tracking and continuous glucose monitoring [4] - The introduction of 1,200 new smartphone-linked ECG patches this year enhances diagnostic precision for cardiologists [4] - Over 40 new remote patient monitoring devices achieved CE Mark approval in Europe in the first half of 2023, reflecting robust acceptance of telemedicine solutions [8] Market Segmentation - Key product categories include diagnostic devices, patient monitoring devices, imaging systems, and consumables [12][13] - Major applications span across cardiology, orthopedics, oncology, and respiratory care [15][16] Major Players - Notable companies in the medical devices market include 3M Co., Abbott Laboratories, Johnson & Johnson, Medtronic Inc., and Siemens Healthcare [11]

Core Viewpoint - The agreement between CFFM and Pulsenmore marks a significant advancement in prenatal care, enabling remote monitoring through home ultrasound services, which enhances patient access and reduces unnecessary visits to diagnostic centers [1][5]. Company Overview - Pulsenmore is focused on transforming maternal health with home-use ultrasound technology that connects mothers and healthcare providers remotely, aiming to improve access and continuity of prenatal care [6]. - CFFM is a prenatal diagnostic center in California that specializes in high-risk pregnancies, managing approximately 1,500 pregnancies annually across two locations in the Los Angeles area [3]. Technological Innovation - Pulsenmore's ultrasound system is designed to empower expectant mothers by providing safe, guided access to ultrasound imaging from home or work, while maintaining close clinician involvement throughout the process [4]. - The collaboration with CFFM will facilitate a remote pregnancy monitoring model that prioritizes patient needs, demonstrating the potential of home-based ultrasound as a routine part of medical care [6]. Market Potential - The agreement with CFFM represents Pulsenmore's first commercial venture in the United States, following recent FDA clearance, and is seen as a crucial step in the company's strategic plan to tap into the U.S. market, which holds significant clinical and business opportunities [5].

Under the agreement, Pulsenmore and Clalit will establish an end-to-end clinical service operated through Beilinson NEXT, Beilinson Medical Center's virtual hospital, enabling eligible patients to perform follicular monitoring scans from home with real-time online guidance and specialist clinical oversight. The agreement allows both Pulsenmore and Clalit to market Pulsenmore FC directly to patients.Pulsenmore previously reported results in June 2025 from a controlled clinical study at Beilinson Medical Cen ...

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292711 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 (214 ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Texas 8099 87-3841292 (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 7524 ...

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...

Core Insights - The Zacks Medical - Outpatient and Home Healthcare industry is rapidly transitioning towards digital healthcare delivery, driven by increased demand for telemedicine and AI technologies [1][2] - The global home healthcare market is projected to grow from $416.4 billion in 2024 to $747.70 billion by 2030, at a CAGR of approximately 10.2% [1] - Key players like Encompass Health Corporation, DaVita Inc., Option Care Health, and The Pennant Group are expected to benefit from these trends [2] Industry Overview - The industry includes companies providing outpatient care and home healthcare using advanced medical technologies for diagnosis, treatment, and rehabilitation [3] - After the pandemic, there has been steady growth in the industry, supported by innovation in services, although inflation may pose challenges [3] - The shift towards value-based care models and increased technology application in healthcare is anticipated to continue [3] Major Trends - The aging global population is a primary driver for home healthcare, increasing demand for chronic disease management and rehabilitation services [4][10] - Outpatient clinics are cost-effective, offering a wide range of treatments without the high costs associated with inpatient care [5] - Home-based care reduces emergency room visits and hospitalizations, leading to significant healthcare savings [6] Technological Advancements - AI plays a crucial role in enhancing patient care through remote monitoring and timely interventions, reducing hospital readmissions [7] - Virtual assistants and chatbots are increasingly used to assist patients in managing their care and scheduling appointments [8] - The utilization of telehealth platforms has surged in home healthcare, particularly in response to the pandemic [9] Staffing Challenges - The U.S. healthcare industry faces significant staffing shortages, particularly among home health aides, exacerbated by high burnout rates [11] Industry Performance - The Zacks Medical - Outpatient and Home Healthcare industry ranks 55, placing it in the top 23% of nearly 250 Zacks industries, indicating positive near-term prospects [12] - The industry has gained 5.1% over the past year, underperforming the S&P 500's 15.2% increase [14] Valuation Metrics - The industry is currently trading at a forward P/E of 18.1X, lower than the S&P 500's 22.9X and the sector's 20.9X [17] - Over the last five years, the industry's P/E has ranged from 16.1X to 23.4X, with a median of 19.2X [18] Company Highlights - **The Pennant Group**: Reported strong revenue growth in Home Health and Hospice Services, with a projected revenue growth of 33.5% for 2025 [20][21] - **Encompass Health**: Opened new hospitals and reported revenue growth, with a projected revenue increase of 10.4% for 2025 [25][26] - **DaVita**: Experienced revenue growth in dialysis services, with a projected revenue increase of 5.8% for 2025 [28][29] - **Option Care Health**: Reported significant revenue growth, with a projected revenue increase of 12.9% for 2025 [32][33]

Healthcare Challenges in China - Chinese patients often prefer specialists in large cities when ill [1] - This preference results in long waiting times and overworked doctors [1] Technological Solutions - China is increasingly exploring high-tech solutions for its medical issues [1] - Telemedicine and AI are being considered as potential solutions [1]